Sandra Herrmann MD, FASN

TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model ⁦@JCI_insight⁩ @VictorCuenca3 @MayoClinicNeph @onconephsociety #onconephrology First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/41785046/

Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention thelancet.com/journals/lance…

TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model ⁦@JCI_insight⁩ @VictorCuenca3 @MayoClinicNeph @onconephsociety #onconephrology First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/41785046/

@SusanQuaggin Congratulations ❤️

A little slower on posts this #WorldKidneyDay and thrilled to share these ten tiny toes 👣 to #SockItToKidneyDisease!! - feeling blessed 😇 to join the #GrandparentsClub ❤️ #LoveYourKidneys

Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia A Systematic Review and Meta-Analysis @wisit661 @SolosVJR @asnpublications @ASNKidney journals.lww.com/kidney360/abst…

TNF-α Blockade Mitigates Immune Checkpoint–Related Nephritis in a Humanized Mouse Model @HerrmannMd insight.jci.org/articles/view/…

Grateful for the outstanding mentorship and collaboration that made this possible. This model opens new avenues to better understand and treat ICI-related nephritis. Looking forward to what’s next for ICI-AIN research!

@wisit661 @MayoClinicNeph 🙏🏼🙏🏼😊

Our @MayoClinicNeph Nephrology Hypertension Grand Rounds Tuesday, March 10, 2026 Immunotherapy-Associated Nephrotoxicity: From Clinical Phenotypes to Translational Mechanisms Very excellent, comprehensive and impactful 👏👏 Professor Dr. Sandra Herrmann @HerrmannMd

@Nephro_Sparks @JCI_insight @VictorCuenca3 @MayoClinicNeph @onconephsociety Thank you !!

@HerrmannMd @JCI_insight @VictorCuenca3 @MayoClinicNeph @onconephsociety Congrats

@PaulHannaMD @MCW_Nephrology @MedicalCollege 👏👏👏congratulations

Honored to receive the Excellence in Patient Experience Award for 2025 @MCW_Nephrology @MedicalCollege

@VictorCuenca3 @josearriolam You did an outstanding job work @VictorCuenca3 ! All your hard work👏👏👏

@josearriolam @JCI_insight @VictorCuenca3 @MayoClinicNeph @onconephsociety Thanks Jose! Big team work! 🙏🏼

@HerrmannMd @JCI_insight @VictorCuenca3 @MayoClinicNeph @onconephsociety Congratulations Dr. Herrmann and team! 👏🏽👏🏽👏🏽

Dr Fervenza @MayoClinicNeph presenting Lupus Nephritis everything you need to know. @SLANH_ @FedericoYandian Medica Uruguaya

Now Dr @ZiZoghby presenting on Hypertension Innovations at Medica Uruguaya & @MayoClinicNeph @FedericoYandian @SLANH_

Dr @PepaSolerR presenting : Treatment with MRAs and GLP1s in CKD, what’s the evidence? Medica Uruguaya &@MayoClinicNeph @SLANH_ @vallhebron @@FedericoYandian

Would you prescribe Bactrim for a patient with glomerular disease receiving rituximab? We recently explored this question. I would love for you to take a look: sciencedirect.com/science/articl… It was a true team effort, led by @LadanZand @MayoClinicNeph we are excited to share the work

Finerenone for Diabetic Kidney Disease in Type 1 Diabetes — A Fine Answer? nejm.org/doi/full/10.10…

In this article we show how the cancer incidence is higher in patients with PLA2R associated MN compared to general population- prostate cancer was one of the most common. Age appropriate cancer screening is essential in this group! mayoclinicproceedings.org/article/S0025-…